A maker of surgical products that repair damaged peripheral nerves, Axogen's lineup includes the Avance Nerve Graft (processed human nerve tissue) and the Axoguard line of porcine-based connectors, protectors, and caps used by surgeons to restore feeling and movement. The business grew out of technology licensed from the University of Florida and took its current form after a 2011 merger, with the FDA approving Avance as a licensed biologic in 2025. A neat quirk: before Avance, the standard repair often meant cutting a healthy nerve from elsewhere in the patient's own body, so the fix created a new injury.
Began Marc AEVP & General Counsel · 2 transactions
+4.8%
54.6K
11.3K
—
—
Levine Alan MDirector · 1 transaction
+38.5%
50.9K
14.2K
—
—
Burke William P. Mr.Director · 1 transaction
+57.6%
38.7K†
14.2K
—
—
Thomas PaulDirector · 1 transaction
+139.5%
32.4K
18.9K
—
—
Weiler Kathy JohnsonDirector · 3 transactions
+115%
14.2K
30.5K
—
16.3K
Johnson JohnDirector · 3 transactions
—
14.2K
25.2K
—
11.1K
Tyndall Joseph A.Director · 1 transaction
+30.3%
14.2K
14.2K
—
—
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -43.2K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.